CLSA Premium Ltd. (HK:6877)
:6877
Top Page
CLSA Premium Ltd.
(6877)
Select Model
Select Model
Rating:52Neutral
Price Target:
HK$0.15
▲(0.00% Upside)
Action:ReiteratedDate:12/30/25
The score is mainly supported by a strong, low-leverage balance sheet and a return to positive net income, but it is held back by weak cash conversion and a 2024 operating/revenue deterioration. Bearish technical positioning and a very high P/E further pressure the overall rating.
Positive Factors
Balance Sheet Strength
A strong balance sheet with low leverage provides financial flexibility and stability, crucial for navigating cyclical downturns in the capital markets industry.
Negative Factors
Revenue Decline
A significant revenue decline raises concerns about market position and demand for services, potentially impacting long-term growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A strong balance sheet with low leverage provides financial flexibility and stability, crucial for navigating cyclical downturns in the capital markets industry.
Read all positive factors
CLSA Premium Ltd. (6877) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$274.49M
Dividend YieldN/A
Average Volume (3M)632.00K
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue Growth-21.08%
EPS Growth-73.08%
CountryHK
Employees13
SectorFinancial
Sector Strength70
IndustryFinancial - Capital Markets
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,033,290,000
10 Day Avg. Volume915,500
30 Day Avg. Volume632,000
Financial Highlights & Ratios
PEG Ratio1.05
Price to Book (P/B)0.82
Price to Sales (P/S)2.30
P/FCF Ratio-10.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CLSA Premium Ltd. Business Overview & Revenue Model
Company Description
Top Eminent Healthcare Group Limited, an investment holding company, sells healthcare products and other services in Australia, Hong Kong, and New Zealand....
How the Company Makes Money
CLSA Premium Ltd. generates revenue primarily through the spreads and commissions charged on the trades executed by its clients on its platforms. The company also earns income from overnight financing fees and other related transactional services....
CLSA Premium Ltd. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
82
Very Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 85.45M | 86.49M | 191.17M | 39.13M | 5.44M | 4.71M |
| Gross Profit | 85.45M | 28.26M | 34.55M | 4.37M | -13.02M | -15.95M |
| EBITDA | 0.00 | -2.54M | 6.97M | -8.17M | -37.05M | -65.72M |
| Net Income | 2.86M | 11.34M | 9.84M | -31.05M | -56.54M | -71.64M |
Balance Sheet | ||||||
| Total Assets | 266.24M | 279.38M | 251.78M | 284.31M | 330.62M | 430.44M |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 205.17M | 222.39M | 211.79M | 234.47M | 289.83M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 9.64M | 10.70M |
| Total Liabilities | 17.99M | 35.08M | 11.91M | 53.51M | 61.86M | 97.38M |
| Stockholders Equity | 248.25M | 244.31M | 239.87M | 230.80M | 268.76M | 333.06M |
Cash Flow | ||||||
| Free Cash Flow | -17.02M | -19.90M | 1.82M | -16.79M | -40.12M | -6.50M |
| Operating Cash Flow | -17.02M | -19.90M | 1.82M | -16.79M | -39.26M | -5.87M |
| Investing Cash Flow | 4.67M | 9.48M | 9.64M | 1.78M | 2.21M | -2.58M |
| Financing Cash Flow | 0.00 | 0.00 | -1.00K | -2.12M | -10.14M | -12.35M |
CLSA Premium Ltd. Technical Analysis
Negative
0.15
Price Trends
0.15
Negative
0.15
Negative
0.21
Negative
Market Momentum
>-0.01
Positive
38.15
Neutral
31.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6877, the sentiment is Negative. The current price of 0.15 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.15, and below the 200-day MA of 0.21, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.15 is Neutral, neither overbought nor oversold. The STOCH value of 31.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6877.
CLSA Premium Ltd. Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$566.23M | 5.92 | 4.26% | ― | 84.88% | 122.45% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
61 Neutral | HK$295.00M | 9.85 | 2.10% | ― | -9.48% | 130.30% | |
55 Neutral | HK$659.21M | 169.91 | 0.83% | 0.33% | -53.05% | -32.93% | |
52 Neutral | HK$274.49M | -42.01 | -1.85% | ― | -21.08% | -73.08% | |
46 Neutral | HK$860.42M | -3.89 | -14.53% | ― | 173.24% | -515.63% | |
46 Neutral | HK$601.14M | 4.56 | 1.42% | 2.39% | -18.72% | -45.10% |
* Financial Sector Average
HK:6877
CLSA Premium Ltd.
0.14
-0.16
-55.00%
HK:0717
Emperor Capital Group Limited
0.08
0.03
68.00%
HK:0952
China Tonghai International Financial Limited
0.14
-0.03
-15.66%
HK:1461
ZHONGTAI FUTURES Company Limited Class H
0.60
0.14
30.43%
HK:2263
Fu Shek Financial Holdings Limited
0.30
0.13
84.37%
HK:3678
Holly Futures Co. Ltd. Class H
2.64
0.56
26.92%
CLSA Premium Ltd. Corporate Events
Top Eminent Healthcare Refreshes Independent Board Leadership With Appointment of Veteran Market Executive
Jan 1, 2026
Top Eminent Healthcare Group Limited has announced that independent non-executive director (INED) and lead INED Mr. Zhou Zuyu will resign from the board and all related committee roles with effect from 31 December 2025 due to other business commit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.